MSD in the UK
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
MSD in the UK
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
-Managing transaminitis with steroids in a patient with intermediate risk advanced RCC
KEYTRUDA (pembrolizumab) RCC /
Products /
Root /

Managing transaminitis with steroids in a patient with intermediate risk advanced RCC

Prescribing Information and SmPC (Great Britain) & Prescribing Information and SmPC (Northern Ireland) [External links]

Intermediate risk

Case study summary

Prof. Tom Powles, Clinical Professor of Genitourinary Oncology at Barts Cancer Centre presents a case study of a 32 year old female with advanced Renal Cell Carcinoma, treated with KEYTRUDA® (pembrolizumab) in combination with axitinib. Following diagnosis for G3 T2 N0 M1 advanced RCC the patient was initiated on systemic therapy. Prof. Tom Powles, describes how we managed the treatment of the patient including the treatment of grade 2 transaminitis.

Intermediate
32
Female
1
Irritable bowel disease, 3 month history of haematurea

Prescribing Information and SmPC (Great Britain) & Prescribing Information and SmPC (Northern Ireland) [External links]

Length: 02:37

Back to the case study hub →

Supporting documentation

Prescribing Information and SmPC (Great Britain) & Prescribing Information and SmPC (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website

GB-RCC-00252 | Date of Preparation: November 2020